

PRECEPTORSHIP PROGRAMME

Gastric Cancer

Multidisciplinary management,
standards of care, therapeutic
targets and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

17-18 NOVEMBER 2021

Co-Chairs

Florian Lordick, Germany

Matthew C. H. Ng, Singapore

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

GASTRIC CANCER

Multidisciplinary management, standards of care and future perspectives

17-18 November 2021

CO-CHAIRS: Florian Lordick, Germany
Matthew C. H. Ng, Singapore

SPEAKERS: Hanneke van Laarhoven, Netherlands
Tony K. H. Lim, Singapore
Brigette Ma, Hong Kong
Joanne Y. Y. Ngeow, Singapore
Sun Young Rha, South Korea
Jimmy B. Y. So, Singapore
Wei Peng Yong, Singapore

LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localized gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localized gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+8 (Singapore Local Time)

Wednesday, 17 November 2021

15:00-15:05 5'	Welcome and introduction	Florian Lordick, DE Matthew C. H. Ng, SG
15:05-17:25 130'	SESSION 1 Epidemiology, pathology and multidisciplinary management of localized gastric cancer	Chair/Moderator: Matthew C. H. Ng, SG
20'	Epidemiology, pathogenesis and molecular subtypes	Brigitte Ma, HK
20'	How pathology can guide treatment: HER2, MSI, PDL1 and EBV	Tony K. H. Lim, SG
20'	Advances in surgery: endoscopic, minimally invasive, optimal nodal dissection and organ-sparing (spleen, omentum)	Jimmy B. Y. So, SG
10'	Discussion	Faculty
16:15-16:25	Break	
25'	Neo- and adjuvant approaches to GC	Matthew C. H. Ng, SG
25'	Neo-adjuvant chemo or chemoradiation for Type1/2 GEJ cancer and the use of immunotherapy and targeted therapy	Florian Lordick, DE
10'	Discussion	Faculty
17:25-18:25	SESSION 2 Participants clinical case discussion	Chair/Moderator: Florian Lordick, DE
60'	Participants clinical case discussion (4x15') (<i>localized</i>)	Faculty

Thursday, 18 November 2021

15:00-15:30 30'	SESSION 3 Cancer genetics	Chair/Moderator: Matthew C. H. Ng, SG
20'	A practical approach to hereditary gastric cancers	Joanne Y. Y. Ngeow, SG
10'	Discussion	Faculty
15:30-17:10 90'	SESSION 4 Metastatic gastric cancer	Chair/Moderator: Florian Lordick, DE
25'	Optimizing chemotherapy and molecularly targeted therapy	Wei Peng Yong, SG
25'	Immunotherapy monotherapy or in combination and when best to give it	Sun Young Rha, KR
10'	Discussion	Faculty
16:30-16:40	Break	
20'	Approaches to treat oligometastatic disease	Hanneke van Laarhoven, NL
10'	Discussion	Faculty

17:10-18:10	SESSION 5 Participants clinical case discussion	Chair/Moderator: Matthew C. H. Ng, SG
60'	Participants clinical case discussion (4x15') (<i>metastatic/unresectable</i>)	Faculty
18:10-18:15 5'	Conclusion and farewell	Florian Lordick, DE Matthew C. H. Ng, SG

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion